| Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis CN Harrison, AM Vannucchi, JJ Kiladjian, HK Al-Ali, H Gisslinger, ... Leukemia 30 (8), 1701-1707, 2016 | 547 | 2016 |
| The market orientation–performance relationship in the context of a developing economy: An empirical analysis R Subramanian, P Gopalakrishna Journal of Business Research 53 (1), 1-13, 2001 | 358 | 2001 |
| Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses S Verstovsek, J Gotlib, RA Mesa, AM Vannucchi, JJ Kiladjian, F Cervantes, ... Journal of hematology & oncology 10, 1-6, 2017 | 330 | 2017 |
| A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis AM Vannucchi, HM Kantarjian, JJ Kiladjian, J Gotlib, F Cervantes, ... haematologica 100 (9), 1139, 2015 | 287 | 2015 |
| Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study DM Ross, T Masszi, MT Gómez Casares, A Hellmann, J Stentoft, ... Journal of cancer research and clinical oncology 144, 945-954, 2018 | 167 | 2018 |
| Influencing satisfaction for dental services. P Gopalakrishna, V Mummalaneni Journal of health care marketing 13 (1), 1993 | 157 | 1993 |
| Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy B Coudert, T Ciuleanu, K Park, YL Wu, G Giaccone, W Brugger, ... Annals of oncology 23 (2), 388-394, 2012 | 144 | 2012 |
| Synergistic effects of market orientation implementation and internalization on firm performance: Direct marketing service provider industry HR Abbu, P Gopalakrishna Journal of Business Research 125, 851-863, 2021 | 114 | 2021 |
| Revisiting the pure versus hybrid dilemma: Porter's generic strategies in a developing economy P Gopalakrishna, R Subramanian Journal of Global Marketing 15 (2), 61-79, 2001 | 107 | 2001 |
| Can advertising be standardized among similar countries? A cluster-based analysis V Sriram, P Gopalakrishna International Journal of Advertising 10 (2), 137-149, 1991 | 104 | 1991 |
| Mediators vs. moderators of patient satisfaction. V Mummalaneni, P Gopalakrishna Journal of Health Care Marketing 15 (4), 1995 | 90 | 1995 |
| The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies V Gupta, C Harrison, EO Hexner, HK Al-Ali, L Foltz, M Montgomery, ... Haematologica 101 (12), e482, 2016 | 79 | 2016 |
| Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy LT Vahdat, AA Garcia, C Vogel, C Pellegrino, DL Lindquist, N Iannotti, ... Breast cancer research and treatment 140, 341-351, 2013 | 77 | 2013 |
| Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis. P Guglielmelli, G Rotunno, C Bogani, C Mannarelli, L Giunti, ... British journal of haematology 173 (6), 2016 | 63 | 2016 |
| Phase IB dose escalation and expansion study of AKT inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer SP Blagden, AL Hamilton, L Mileshkin, S Wong, A Michael, M Hall, ... Clinical Cancer Research 25 (5), 1472-1478, 2019 | 54 | 2019 |
| Some people just want to read: The roles of age, interactivity, and perceived usefulness of print in the consumption of digital information products CP Kirk, L Chiagouris, P Gopalakrishna Journal of retailing and consumer services 19 (1), 168-178, 2012 | 53 | 2012 |
| Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis CN Harrison, AM Vannucchi, JJ Kiladjian, HK Al-Ali, H Gisslinger, ... Leukemia 31 (3), 775, 2017 | 50 | 2017 |
| The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of … MF McMullin, CN Harrison, D Niederwieser, H Demuynck, N Jäkel, ... Experimental hematology & oncology 4, 1-6, 2015 | 48 | 2015 |
| Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (pts) with myelofibrosis (MF) CN Harrison, JJ Kiladjian, FH Heidel, AM Vannucchi, F Passamonti, ... Blood 126 (23), 4060, 2015 | 46 | 2015 |
| The digital transformation of the grocery business-driven by consumers, powered by technology, and accelerated by the COVID-19 pandemic HR Abbu, D Fleischmann, P Gopalakrishna Trends and Applications in Information Systems and Technologies: Volume 3 9 …, 2021 | 41 | 2021 |
